Zeo partners to commercialize Cytora's oral mucosal stem cell therapy under Florida law

Zeo ScientifiX, Inc.

Zeo gets exclusive U.S. commercial rights to Cytora's allogeneic oral mucosal stem cell therapy (hOMSC200).
Initial commercialization under Florida SB 1768 for diabetic foot ulcers; estimated 125,000 new patients annually in Florida alone.
Phase 1/2a trial showed favorable safety and statistically significant complete wound closure in 27-month average-open ulcers.
Made Scientific handles GMP manufacturing at Princeton, NJ; Zeo provides market access, distribution, and clinical site management.
Partnership also plans U.S. FDA Phase 2b trial aiming for approved license.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.